Modern Approaches to H. pylori Eradication Therapy in Adults (Literature Review and Resolution of Experts Council)
Authors:
- V. Т. IvashkinVIV. Т. Ivashkin
- A. I. UlyaninAUA. I. Ulyanin
- I. V. MayevIMI. V. Mayev
- R. S. KozlovR. S. Kozlov
- M. A. LivzanM. A. Livzan
- S. R. AbdulkhakovSAS. R. Abdulkhakov
- O. P. AlekseyevaOAO. P. Alekseyeva
- S. A. AlekseyenkoSAS. A. Alekseyenko
- D. S. BordinD. S. Bordin
- N. N. DekhnichNDN. N. Dekhnich
- N. V. KorochyanskayaNKN. V. Korochyanskaya
- T. L. LapinaTLT. L. Lapina
Open Access
- 30 December 2022
- journal article
- research article
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 32 (6) , 7-19
Abstract
Aim: to analyze current approaches to H. pylori eradication therapy in adults and present the materials of Experts Council held on December 9, 2022 in Moscow.General statements. H. pylori infection is the main etiological factor of gastritis, peptic ulcer, and gastric cancer. Eradication of H. pylori is recognized as a necessary measure to reduce the incidence of these diseases. The approaches to selecting an eradication regimen should be optimized to take into account epidemiological trends and achieve better treatment outcomes. The updated Maastricht VI Consensus Report presents the means to overcome the difficulties in selecting an approach to the treatment of H. pylori infection. However, eradication therapy remains challenging due to adverse events (primarily antibiotic-associated diarrhea), poor treatment tolerance and patient compliance. Eradication therapy can be optimized by supplementing treatment regimens with strain-specific probiotics that reduce adverse events, improve patient compliance and eradication rates, such as Saccharomyces boulardii CNCM I-745 strain with established efficacy.Conclusion. The inclusion of certain probiotics in eradication regimens improves treatment tolerance, reduces the risk of adverse events, improves patient compliance and eradication rates.Keywords
This publication has 48 references indexed in Scilit:
- Influence of Saccharomyces boulardii CNCM I-745 on the gut-associated immune systemClinical and Experimental Gastroenterology, 2016
- Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement InitiativeEndoscopy, 2016
- Dual-priming oligonucleotide-based multiplex PCR using tissue samples from the rapid urease test kit for the detection of Helicobacter pylori in bleeding peptic ulcersDigestive and Liver Disease, 2016
- A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesionsEndoscopy, 2016
- Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysisExperimental and Therapeutic Medicine, 2015
- Probiotics inHelicobacter pylorieradication therapy: A systematic review and meta-analysisWorld Journal of Gastroenterology, 2015
- Saccharomyces boulardiiCNCM I-745 in different clinical conditionsExpert Opinion on Biological Therapy, 2014
- History ofHelicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancerWorld Journal of Gastroenterology, 2014
- Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatmentAlimentary Pharmacology & Therapeutics, 2010
- Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pyloriJournal of Clinical Pathology, 2006